Abstract
Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m2 days 1-3, ifosfamide 1500 mg/m2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m2 days 1 and 5; filgrastim was given at the dose of 300 microg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Cisplatin / administration & dosage
-
Disease Progression
-
Disease-Free Survival
-
Female
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Humans
-
Ifosfamide / administration & dosage
-
Injections, Subcutaneous
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Mesna / administration & dosage
-
Middle Aged
-
Protective Agents / administration & dosage
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
Substances
-
Protective Agents
-
Granulocyte Colony-Stimulating Factor
-
Vinblastine
-
Mesna
-
Cisplatin
-
Ifosfamide